|Articles|April 7, 2020

Thermo and NanoPin Announce Collaboration

Thermo Fisher Scientific has announced a collaboration with NanoPin Technologies, Inc. to improve blood-based infectious disease detection technology through the development of highly sensitive LC–MS‑based workflows.

Thermo Fisher Scientific (Waltham, Massachusetts, USA) has announced a collaboration with NanoPin Technologies, Inc. (New Orleans, Louisiana, USA) to improve blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography–mass spectrometry (LC–MS)‑based workflows.

The companies will combine Thermo Fisher’s LC–MS technology with NanoPin’s diagnostic platform to detect disease-related antigens directly from patient blood samples, which will lead to the development of sensitive clinical assays for infectious disease. The overall aim is to reduce diagnosis times and improve the determination of infection stage, as well as monitor patient response to prescribed treatments.

For more information please visit: www.thermofisher.com


Related to this article

LC-MS/MS Method Detects Propofol via Metabolite
Koji Yamaguchi of the International University of Health and Welfare (Narita, Japan) discusses a novel derivatized liquid chromatography-tandem mass spectrometry (LC-MS/MS) method plus propofol glucuronide (PRG) marker which improves forensic propofol detection.